Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.
Int J Dermatol
; 63(7): 922-928, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38284277
ABSTRACT
BACKGROUND:
Brodalumab is a monoclonal antibody and IL-17 RA inhibitor that is approved for the treatment of moderate-to-severe psoriasis. The present study aims to estimate the drug survival (DS), effectiveness, and safety of brodalumab over a period of 156 weeks.METHODS:
The primary objectives were (i) to determine the treatment response rate at Weeks 16, 28, 52, 78, 104, and 156 as defined by PASI100, PASI90, and an absolute PASI ≤ 3 and (ii) long-term DS. Secondary objectives included the evaluation of possible predictive factors associated with the achievement of response outcomes, and possible predictive factors associated with lower DS.RESULTS:
The treatment response was rapid, with 80.3% of patients achieving PASI ≤ 3, 66% PASI90, and 54.3% the complete clearance of disease at Week 16. The response improved at Week 28, when a plateau was achieved with mild loss of response at later time points, in particular for PASI100 and PASI90 in 55.2 and 65.5% of patients, respectively, at Week 156. After 156 weeks of treatment, 66.22% of patients were still on therapy, and the previous use of IL-17 inhibitors appeared to be associated with an increased risk of treatment discontinuation (HR 2.51, CI 1.06-5.98, P = 0.037), and achievement of PASI ≤ 3 until Week 16 with less risk (HR 0.27 CI 0.14-0.51, P < 0.001). Bio-naïve status was favorably associated with treatment response, while high BMI negatively affected the achievement of outcomes.CONCLUSION:
Our study confirms the good effectiveness and favorable safety profile of brodalumab in a real-world setting for up to 3 years of treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Índice de Gravidade de Doença
/
Anticorpos Monoclonais Humanizados
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article